Pregnancy in women with dilated cardiomyopathy

Eera Fatima Bangi, Nicolle Maikawa, Amandeep Kaur, Rahul Jain, Rohit Jain

Research output: Contribution to journalReview articlepeer-review


Only a few studies describe the pathophysiology and outcomes of dilated cardiomyopathy (DCM) in pregnancy, which the authors aim to review here. DCM causes enlargement of the ventricles and reduced systolic function. Fluid overload and raised cardiac output in pregnancy may contribute to cardiac complications that lead to cardiac remodeling and heart failure, a common cause of maternal mortality. The risk of cardiac complications is higher in women with New York Heart Association class III and IV. Fetal and neonatal complications are common with coexisting obstetric risk factors. Hence, prepregnancy counseling and a multi-disciplinary approach are essential. Renin-angiotensin-aldosterone system blockers prevent cardiac remodeling but are teratogenic. Drugs, such as β-blockers to control cardiac remodeling, thiazide diuretics to reduce preload, hydralazine and nitrates to reduce afterload and digoxin to increase inotropy, are safe and should be used to manage DCM in pregnancy.

Original languageEnglish (US)
Pages (from-to)661-667
Number of pages7
JournalFuture Cardiology
Issue number8
StatePublished - Aug 2022

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pregnancy in women with dilated cardiomyopathy'. Together they form a unique fingerprint.

Cite this